Prakash Vikram, Batanian Jacqueline R, Guzman Miguel A, Duncavage Eric J, Geller Thomas J
Department of Neurology, Cardinal Glennon Children's Hospital, Saint Louis University School of Medicine, St Louis, Missouri.
Department of Pathology, Cardinal Glennon Children's Hospital, Saint Louis University School of Medicine, St Louis, Missouri.
Pediatr Neurol. 2014 Jul;51(1):138-43. doi: 10.1016/j.pediatrneurol.2014.02.012. Epub 2014 Feb 22.
Desmoplastic infantile ganglioglioma is a rare intracranial neoplasm classified as World Health Organization grade I tumor under neuronal and mixed neuronal-glial tumors (2007 World Health Organization brain tumor classification). It is usually a good prognosis, but 40% of patients require further medical, radiation, and/or surgical intervention, and 15% develop leptomeningeal spread or die from desmoplastic infantile ganglioglioma. Transformation to malignant glioblastoma occurs, but the genetic alterations associated with the transformation are generally unknown.
We describe a desmoplastic infantile ganglioglioma in a 2-month-old boy, which showed aggressive behavior, requiring debulking at 2.5 months of age and chemotherapy at 10 months of age after tumor progression. At 8.5 years of age he developed malignant transformation to glioblastoma. Chromosome microarray analysis using oligo array and genomic sequencing was performed on the biopsy specimen from 2 months of age and on the subsequent transformed malignant glioblastoma.
After being clinically stable for 7.5-years, transformation to glioblastoma transformation occurred. He did well for 1 year but subsequently died from tumor progression. Chromosome microarray analysis using oligo array performed on the biopsy specimen obtained at 2 months of age did not reveal significant abnormalities; but there were significant genomic deletions and duplications associated with the glioblastoma. These included multiple genomic losses involving 4q and Y, gains of 5q, and amplification of 12q14. Genomic sequencing revealed a single nucleotide variant, p.R248Q in exon 7 of TP53, in the primary desmoplastic infantile ganglioglioma and the glioblastoma multiforme.
The nonsynonymous variant (p.R248Q in exon 7) of the TP53 gene is predicted to alter the structure of the L2/L3 motif of the DNA binding domain of p53 protein. It was detected in the primary desmoplastic infantile ganglioglioma and glioblastoma multiforme. This child illustrates the rare recurrence of desmoplastic infantile ganglioglioma with malignant transformation to glioblastoma caused by a nonsynonymous TP53 mutation, providing explanation for other rare benign tumor transformations. The TP53 gene is a known primary site of genetic alteration that predisposes to malignant tumors, and this case indicates that it might also be involved in the behavior and outcome of desmoplastic infantile ganglioglioma. Therefore more genetic testing is recommended on desmoplastic infantile ganglioglioma tumors, which may provide biologic prognostic markers.
促纤维增生性婴儿型节细胞胶质瘤是一种罕见的颅内肿瘤,在世界卫生组织(2007年世界卫生组织脑肿瘤分类)的神经元及混合性神经元 - 胶质细胞肿瘤中被归类为I级肿瘤。其预后通常较好,但40%的患者需要进一步的药物、放疗和/或手术干预,15%的患者会发生软脑膜播散或死于促纤维增生性婴儿型节细胞胶质瘤。会发生向恶性胶质母细胞瘤的转化,但与该转化相关的基因改变通常不明。
我们描述了一名2个月大男孩的促纤维增生性婴儿型节细胞胶质瘤,该肿瘤表现出侵袭性,在2.5个月大时需要进行肿瘤减积手术,在肿瘤进展后10个月大时接受化疗。8.5岁时,他发生了向胶质母细胞瘤的恶性转化。对2个月大时的活检标本以及随后转化的恶性胶质母细胞瘤进行了使用寡核苷酸芯片的染色体微阵列分析和基因组测序。
在临床稳定7.5年后,发生了向胶质母细胞瘤的转化。他情况良好地维持了1年,但随后死于肿瘤进展。对2个月大时获取的活检标本进行的使用寡核苷酸芯片的染色体微阵列分析未发现明显异常;但在胶质母细胞瘤中存在显著的基因组缺失和重复。这些包括涉及4号染色体长臂和Y染色体的多个基因组缺失、5号染色体长臂的增加以及12号染色体长臂14区的扩增。基因组测序在原发性促纤维增生性婴儿型节细胞胶质瘤和多形性胶质母细胞瘤中均发现了一个单核苷酸变异,即TP53基因外显子7中的p.R248Q。
TP53基因的非同义变异(外显子7中的p.R248Q)预计会改变p53蛋白DNA结合域的L2/L3基序结构。它在原发性促纤维增生性婴儿型节细胞胶质瘤和多形性胶质母细胞瘤中均被检测到。这名儿童说明了促纤维增生性婴儿型节细胞胶质瘤罕见地复发并因TP53非同义突变向胶质母细胞瘤恶性转化的情况,为其他罕见的良性肿瘤转化提供了解释。TP53基因是已知的易导致恶性肿瘤的基因改变主要位点,该病例表明它可能也参与了促纤维增生性婴儿型节细胞胶质瘤的行为和转归。因此,建议对促纤维增生性婴儿型节细胞胶质瘤肿瘤进行更多的基因检测,这可能会提供生物学预后标志物。